Neurol. pro Praxi, 2006; 6: 304

Novinky v léčbě cévních mozkových příhod

MUDr. Robert Mikulík
I. neurologická klinika LF MU a FN u sv. Anny Brno

Vysoká mortalita a morbidita činí cévní mozkové příhody (CMP) jedny z nejzávažnějších onemocnění vůbec. Tradičně byly vnímány jako velmi špatně léčitelné, protože neexistovala žádná možnost významného ovlivnění průběhu onemocnění. Tato skutečnost se radikálně změnila. Toto jsou ústřední body nejvýznamnějších změn seřazených chronologicky:

Published: February 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mikulík R. Novinky v léčbě cévních mozkových příhod. Neurol. praxi. 2006;7(6):304.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alexandrov AV et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004; 351 (21): 2170-2178. Go to original source... Go to PubMed...
    2. del Zoppo GJ et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998; 29 (1): 4-11. Go to original source... Go to PubMed...
    3. Furlan AJ et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37 (5): 1227-1231. Go to original source... Go to PubMed...
    4. Furlan A. et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282 (21): 2003-2011. Go to original source... Go to PubMed...
    5. Hacke W et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363 (9411): 768-774. Go to original source... Go to PubMed...
    6. Hacke W et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36 (1): 66-73. Go to original source... Go to PubMed...
    7. Mayer SA et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352 (8): 777-785. Go to original source... Go to PubMed...
    8. Mendelow AD et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005; 365 (9457): 387-397. Go to original source...
    9. Smith WS. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol 2006; 27 (6): 1177-1182.
    10. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333 (24): 1581-1587.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.